Garth Rapeport, MD  

Chief Development Officer, RIGImmune Inc.  

Dr. Rapeport has over two decades of experience in drug discovery and the identification of novel, disease-modifying treatments. As the previous co-founder and CEO of Pulmocide and Respivert, he was at the forefront of innovative therapeutics to treat severe asthma and developed new generation inhaled antiviral and antifungal agents.  

He is currently a visiting Professor at the National Heart & Lung Institute, Imperial College School of Medicine in London and Entrepreneur in Residence at F Prime Capital. Dr. Rapeport is a medical graduate who undertook post-graduate training at the Universities of Glasgow and Oxford. After working at Pfizer Research in the UK he moved to GSK where he was SVP of Drug Discovery in the Respiratory area in which he led the discovery and early development of new inhaled therapies for asthma and COPD.  

Back to About Us